These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 23896857)

  • 1. Number needed to harm: its limitations in psychotropic drug safety research.
    Safer DJ; Zito JM
    J Nerv Ment Dis; 2013 Aug; 201(8):714-8. PubMed ID: 23896857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number needed to harm can be clinically useful: a response to Safer and Zito.
    Citrome L; Ketter TA
    J Nerv Ment Dis; 2013 Nov; 201(11):1001-2. PubMed ID: 24177490
    [No Abstract]   [Full Text] [Related]  

  • 3. Number needed to harm.
    Safer DJ; Zito JM
    J Nerv Ment Dis; 2013 Nov; 201(11):1003. PubMed ID: 24177491
    [No Abstract]   [Full Text] [Related]  

  • 4. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-grouped differences in adverse drug events from psychotropic medication.
    Safer DJ
    J Child Adolesc Psychopharmacol; 2011 Aug; 21(4):299-309. PubMed ID: 21851188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication safety program reduces adverse drug events in a community hospital.
    Cohen MM; Kimmel NL; Benage MK; Cox MJ; Sanders N; Spence D; Chen J
    Qual Saf Health Care; 2005 Jun; 14(3):169-74. PubMed ID: 15933311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns.
    Hughes S; Cohen D; Johnson R
    Int J Risk Saf Med; 2016 Aug; 28(2):101-14. PubMed ID: 27567767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in medication clinical trials.
    Rudorfer MV
    Psychopharmacol Bull; 1993; 29(1):35-44. PubMed ID: 8378510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000.
    Greenhill LL; Vitiello B; Abikoff H; Levine J; March JS; Riddle MA; Capasso L; Cooper TB; Davies M; Fisher P; Findling RL; Fried J; Labellarte MJ; McCracken JT; McMahon D; Robinson J; Skrobala A; Scahill L; Varipatis E; Walkup JT; Zito JM
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):651-5. PubMed ID: 12921472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting of harm in randomized controlled trials published in the urological literature.
    Breau RH; Gaboury I; Scales CD; Fesperman SF; Watterson JD; Dahm P
    J Urol; 2010 May; 183(5):1693-7. PubMed ID: 20299044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicating the benefits and harms of treatments.
    Akobeng AK
    Arch Dis Child; 2008 Aug; 93(8):710-3. PubMed ID: 18456681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number needed to harm: is it too optimistic?
    Massel D
    Can J Cardiol; 2003 Dec; 19(13):1490-2. PubMed ID: 14760438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process.
    Linden M
    Psychopharmacol Bull; 1993; 29(1):51-6. PubMed ID: 8378512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The number needed to treat as a measure of effect in the treatment of primary immune thrombocytopenia].
    Vizcaíno G; Vizcaíno-Carruyo J
    Invest Clin; 2012 Mar; 53(1):16-27. PubMed ID: 22524105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative vs. absolute measures of benefit and risk: what's the difference?
    Citrome L
    Acta Psychiatr Scand; 2010 Feb; 121(2):94-102. PubMed ID: 19694632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical problems in the reporting of clinical trials. A survey of three medical journals.
    Pocock SJ; Hughes MD; Lee RJ
    N Engl J Med; 1987 Aug; 317(7):426-32. PubMed ID: 3614286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotropic drugs and paediatrics: a critical need for more clinical trials.
    Tishler CL; Reiss NS
    J Med Ethics; 2012 Apr; 38(4):250-2. PubMed ID: 22048850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood dyscrasias induced by psychotropic drugs.
    Stübner S; Grohmann R; Engel R; Bandelow B; Ludwig WD; Wagner G; Müller-Oerlinghausen B; Möller HJ; Hippius H; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S70-8. PubMed ID: 15052517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.